BEMA Buprenorphine is a transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, which incorporates a bioerodible mucoadhesive (BEMA) technology.
BEMA Buprenorphine is currently in phase III trials to treat moderate to severe chronic pain.
The transaction includes an upfront payment of $30m to BioDelivery Sciences International, royalties of net sales, and up to around $150m in milestones contingent upon achievement of pre-defined, late state clinical and regulatory events and achievement of certain sales targets.
Endo Pharmaceuticals CEO and president Dave Holveck said the company is focused on providing solutions for the development and commercialization of products related to management of pain.
"The addition of BEMA Buprenorphine will broaden Endo’s portfolio of pain therapeutics, allowing us to offer an integrated suite of products that currently include Opana ER, Voltaren Gel and Lidoderm, as well as a broad range of generic pain products," Holveck added.